Randomised double-blind placebo-controlled study of the effect of inhibition of nitric oxide synthesis in bradykinin-induced asthma

Background Bronchoconstriction induced by bradykinin is reduced by the release oi nitric oxide (NO) in the airways of guineapigs. Inhaled NO is known to cause bronchodilatation in asthmatic patients. To find out the role of endogenous NO in airway response to bradykinin in asthma, we examined the effect of the NO synthase inhibitor N-G-monomethyl-L-arginine (L-MMMA) on broncho-constriction after bradykinin challenge in ten patients with mild asthma. Methods The study had a randomised, double-blind, placebo-controlled, cross-over design. Participants were studied during two phases, each consisting of 2 study days. After baseline measurements oi forced expiratory volume in 1 s (FEV(1)) participants inhaled an aerosol of L-NMMA or saline (placebo). After 5 min, saline and doubling doses of bradykinin (from 0.25 nmol) were inhaled until FEV(1) fell by at least 20% of the post-saline value. The effect of L-NMMA and placebo an airway response to doubling concentrations of methacholine (from 0.03 mg/mL) was then examined. We also assessed the effect of the inactive enantiomer of L-NMMA, D-NMMA, and placebo on bronchoconstriction after bradykinin or methacholine challenge in six of the participants. Findings The geometric mean of the provocative dose producing a 20% fall in FEV(1) to bradykinin was 138.0 nmol (range 48.2-475.2 nmol) after placebo and 11.2 nmol (range 0.9-51.3 nmol) after L-NMMA (p<0.01). L-NMMA also caused a decrease in the provocative concentration of methacholine producing a 20% fall in FEV(1) from 0.93 mg/mL (range 0.12-2.55 mg/mL) to 0.38 mg/mL (range 0.06-0.92 mg/mL; p<0.01). In contrast, D-NMMA did not affect airway response to bradykinin or methacholine. Interpretation The results suggest that bronchoconstriction after bradykinin inhalation is greatly inhibited by the formation of NO in airways of asthmatic patients and that NO could have a bronchoprotective role in asthma.